[VIRTUAL] DANUBE post-hoc analysis: Outcomes for durvalumab with or without tremelimumab by cisplatin eligibility and PD-L1 biomarker status in metastatic urothelial carcinoma

[VIRTUAL] Pembrolizumab (pembro) vs. placebo as post nephrectomy adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study

[VIRTUAL] Abiraterone acetate plus prednisone added to androgen deprivation therapy and docetaxel in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): detailed analysis of radiographic progression-free survival in the PEACE-1 phase 3 trial

[VIRTUAL] TheraP Phase 2 trial of Lu-PSMA-617 versus cabazitaxel: Results and contrasts to VISION

[VIRTUAL] Phase 3 study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)

[VIRTUAL] The effect of a neoadjuvant instillation of chemotherapy in the prevention of recurrences of non-muscle invasive bladder cancer. Preliminary results of the PRECAVE prospective, controlled, randomized clinical trial

[VIRTUAL] Impact of Prior Local Trecepherapy (PLT) on survival in metastatic castration resistant prostate cancer (mCRPC). Results from COU-AA-302 trial

[VIRTUAL] Metastatic prostate cancer patients’ Attitudes towards Treatment of the local Tumour and metastasis Evaluative Research (IP5-MATTER): A multicentre, discrete choice experiment trial-in-progress

[VIRTUAL] Is fast-MRI as accurate as multi-parametric MRI in the detection of clinically significant prostate cancer in biopsy naïve men? A prospective, single centre, non-inferiority randomized trial

[VIRTUAL] Prostate cancer screening using prostate-specific antigen, a multiplex blood-test, magnetic resonance imaging and targeted prostate biopsies: The STHLM3MRI trial

[VIRTUAL] Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)

[VIRTUAL] Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

[VIRTUAL] Optimal timing of perioperative systemic therapy for high-risk upper urinary tract cancer: Adjuvant

[VIRTUAL] PSMA in diagnostics and treatment

[VIRTUAL] Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study